Lakeside Advisors INC. Sells 200 Shares of Novo Nordisk A/S $NVO

Lakeside Advisors INC. trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 1.0% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 18,850 shares of the company’s stock after selling 200 shares during the quarter. Novo Nordisk A/S makes up 0.8% of Lakeside Advisors INC.’s investment portfolio, making the stock its 23rd largest position. Lakeside Advisors INC.’s holdings in Novo Nordisk A/S were worth $1,301,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Copeland Capital Management LLC grew its position in Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after acquiring an additional 255 shares in the last quarter. North Capital Inc. bought a new stake in Novo Nordisk A/S in the first quarter worth approximately $27,000. Stone House Investment Management LLC bought a new stake in Novo Nordisk A/S in the first quarter worth approximately $30,000. Disciplina Capital Management LLC lifted its stake in shares of Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 297 shares during the last quarter. Finally, Spirit of America Management Corp NY acquired a new stake in shares of Novo Nordisk A/S in the first quarter worth $35,000. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Novo Nordisk A/S in a research note on Saturday, September 27th. Rothschild Redb upgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th. Morgan Stanley cut shares of Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and reduced their price objective for the stock from $59.00 to $47.00 in a research note on Monday, September 29th. TD Cowen reduced their price objective on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, August 19th. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.50.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $59.10 on Wednesday. The stock has a market cap of $263.90 billion, a P/E ratio of 16.24, a PEG ratio of 2.66 and a beta of 0.68. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $120.56. The company has a fifty day moving average price of $54.84 and a 200 day moving average price of $63.48. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were issued a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S’s payout ratio is 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.